Antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) have been described in patients with neuromyelitis optica spectrum disorders (NMOSD) without aquaporin-4 antibodies (AQP4-IgG). We aimed to identify the proportion of AQP4-IgG-negative NMOSD patients who are seropositive for MOG-IgG. In a cross sectional study, we reviewed all patients seen in the National NMO clinic over the last 4 years (after the availability of MOG-IgG testing), including clinical information, MRI, and antibody tests. 261 unique patients were identified. 132 cases satisfied the 2015 NMOSD diagnostic criteria. Of these, 96 (73%) were AQP4-IgG positive and 36 (27%) were AQP4-IgG negative. These 36 patients were tested for MOG-IgG and 15/36 (42%) tested positive. 20% (25/125) of the patients who did not satisfy NMOSD criteria had MOG-IgG. Approximately half of seronegative NMOSD is MOG-Ig seropositive and one in five of non-NMOSD/non-MS demyelination is MOG-IgG positive. Since MOG-associated demyelinating disease is likely different from AQP4-IgG disease in terms of underlying disease mechanisms, relapse risk and possibly treatment, testing for MOG-IgG in patients with AQP4-IgG-negative NMOSD and other non-MS demyelination may have significant implications to management and clinical trials.
Introduction
73–90% of neuromyelitis optica spectrum disorder (NMOSD) patients diagnosed according to the 2015 International panel on NMO diagnosis have aquaporin-4 antibodies (AQP4-IgG) [1, 2]. It is presumed that at least a proportion of the remaining 10–27% of patients, classified as seronegative NMOSD have another disease specific antibody. Antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) have been increasingly reported in a variety of CNS neuroinflammatory conditions including patients with phenotypes typical for NMOSD [3]. We aimed to determine the prevalence of MOG-IgG in AQP4-IgG-negative NMOSD.
Methods
The Walton Centre Neurosciences NHS Trust in Liverpool, United Kingdom, is a tertiary neurology hospital that hosts one of the two national multidisciplinary specialist clinics for patients with NMOSD and non-MS demyelinating disorders as part of the UK NMOSD service. We systematically reviewed all patients seen in this clinic over the last 4 years (after the availability of MOG-IgG testing), including clinical information, MRI, and antibody tests. Both AQP4-IgG and MOG-IgG were tested using a validated live cell-based assay with high specificity (John Radcliffe Hospital, Oxford, UK) [4, 5]. This study was approved by Research Ethics Service, NRES Committee London—Hampstead, Ref. no. 15/LO/1433.
Anzeige
Results
261 unique patients with non-MS/atypical CNS inflammatory conditions attended the clinic and were assessed for NMOSD. All patients were tested for AQP4-IgG. 132 cases satisfied the 2015 NMOSD diagnostic criteria. Of these, 96 (73%) were AQP4-IgG positive and 36 (27%) AQP4-IgG negative. These 36 patients, were tested for MOG-IgG and 15/36 (42%) tested positive. This would account for 11% (15/132) of the total cohort of NMOSD patients (Fig. 1; Table 1). All MOG-IgG-negative patients were Caucasians with a median age of onset of 18 years (8–44 years) and median disease duration of 4.7 years (2–16 years). The predominant clinical phenotype of the demyelinating event was ON (60%), TM (21%), brain (12%), and brainstem (4%).
Fig. 1
Classification of non-MS/atypical demyelination based on 2015 NMOSD criteria, AQP4-IgG, and MOG-IgG testing. NMOSD neuromyelitis optica spectrum disorder, AQP4 IgG Antibody to aquaporin 4, MOG-IgG antibody to myelin oligodendrocyte glycoprotein, OSD optico-spinal demyelination with normal brain MRI
Table 1
Demographic, clinical, and radiological characteristics of the 15 NMOSD patients with MOG-IgG
Patient no.
Age
Sex
Age at onset
Disease duration (years)
Course
Total no. of events
Clinical phenotype (no. of attacks)
First inter-attack interval
Spinal MRI
Baseline brain MRI
CSF oligoclonal bands
EDSS
Current treatment
1
31
F
18
13.4
R
13
ON (13)
TM (1)
3 years
LETM
Normal
Negative
4
Subcutaneous IGs (immunoglobulins) and oral prednisolone
2
55
M
44
11
R
7
ON (2)
TM (1) brainstem (1) brain syndrome (5)
7 years
Short mid thoracic lesion
Brain stem, cortical and subcortical extensive demy
Positive
3.5
Steroid & mycophenolate
3
31
F
15
16.4
R
2
ON (1)
TM (1)
4 years
LETM
Normal
Negative
9
Azathioprine and oral prednisolone
4
21
M
18
2.5
R
5
Brain stem (1)
Brain syndrome (1)
TM (1)
ON (5)
2 months
Multiple short lesions on thoracic cord
Large area of high T2 signal in the posterior brainstem both sides of mid brain
Negative
1.5
Azathioprine switched to rituximab
5
22
M
17
4.7
R
>7
ON (>7) and TM (2)
2 months
LETM
Normal
Unknown
3
Tocilizumab, IVIG six weekly and oral prednisolone
6
30
F
28
2
R
2
ON (1)
TM (1)
1 year
LETM
Cerebral ring enhancing lesion supracallosal subcortical
Negative
0
Mycophenolate
7
23
F
8
14.4
R
3
ON (2) TM (2) Brain syndrome (1)
3 years
LETM
Multiple non-specific white matter lesions
Negative
6
Azathioprine and oral prednisolone
8
24
F
17
6.9
R
2
ON (1)
TM (1)
Brain syndrome (1)
3 months
LETM
Brainstem, left cerebral peduncle, and few non-specific white matter lesions
Negative
1
Azathioprine and oral prednisolone
9
14
F
10
4
R
3
Brain syndrome (1) ON (3)
TM (1)
3 month
LETM
Bilateral hemispheric white matter changes
Negative
2.5
Rituximab and mycophenolate
10
28
M
19
8.2
R
4
ON (3)
TM (1)
6 years
LETM
Normal
Unknown
4
Mycophenolate
11
44
M
13
31
R
5
ON (3)
TM (2)
17 years
LETM
Normal
Negative
3.5
Azathioprine
12
39
F
36
3.1
R
2
Brain stem (1)
ON (2)
2.2 years
Normal
Lesion on pons
Negative (161)
3
Mycophenolate and oral prednisolone
13
42
M
38
3.6
R
2
TM (1)
Brain stem (1)
2 months
LETM
Peri ependymal pons lesion
Unknown
6
Azathioprine and oral prednisolone
14
28
M
26
2
Single event
1
ON + LETM
Simultaneously
LETM
Normal
Positive
1.5
Mycophenolate
15
45
M
40
5
Single event
1
ON + LETM
Simultaneously
LETM
Normal
Negative
2
None
F female, M male, R relapsing, ON optic neuritis, TM transverse myelitis, LETM longitudinally extensive transverse myelitis, and IVIG intravenous immunoglobulins
×
While we tested all AQP4-IgG-negative patients for MOG-IgG (n = 36), only a proportion (33%) of AQP4-IgG-positive patients (n = 32) were tested (as double positives are exceptionally rare) (Fig. 1). None were definitely positive. However, one patient was ‘low positive/possibly negative. This patient with one episode of long myelitis also had antinuclear antibodies (1/80 titre with homogenous pattern (nuclear antigens all negative) and was ‘low positive’ for anti-glycine antibodies too. The significance of the MOG-IgG in the context of these additional antibodies is uncertain and may reflect a heightened humoral autoimmune response rather than truly pathogenic dual positivity. This patient has not been included in the MOG cohort in this paper.
We also tested the majority of patients with a demyelinating syndrome referred to the service who did not fulfill the NMOSD criteria (125/129, 97%). Twenty-five (20%) were positive for MOG-IgG. Details of these cases will be the subject of an upcoming separate research paper and are not discussed further here.
We also assessed how many of the MOG-IgG patients with NMOSD phenotype had a relapsing course. Thirteen patients (86%) had a relapsing course. However, a relapsing course was the reason for referral to the clinic in the first place (n = 13/13). The median duration of illness for the relapsing patients was 4.7 years (2–16 years). The median inter-attack interval was 1 year (0.16–17) and median EDSS in the relapsing MOG group at last follow-up was 3 (0–9, Table 1). All relapsing patient are on immunosuppressants (Table 1).
Anzeige
We also assessed the proportion of patients with optic neuritis and long myelitis who fulfill Wingerchuk 2006 criteria [6] that are MOG-IgG positive, as this is a clinical question often posed. Of the whole cohort of 261 patients, 75 patients had long myelitis and optic neuritis. Of these 49 were AQP4-IgG positive (66%) and 10 were MOG-IgG positive (13%, or 38% of AQP4-IgG-negative patients) and 16 remained seronegative (21%). Serial testing where done in 14/15 patients (13 relapsing); MOG-IgG was detected in all. Treatment with steroid or immunosuppression does not seem to have an effect on MOG-IgG serostatus in this cohort of predominantly relapsing patients (Table 2).
Table 2
MOG-IgG testing in relation to disease course and immunosuppressive treatment. NA: not available
Patient no.
Date of onset
Date of first relapse
Last relapse
Date of start on steroid
Date of start on maintenance immunosuppressive treatment
First-positive MOG-IgG test
Subsequent MOG test year
Titre
Comments
1
Jan 02
May 05
Jul 05
Jan 08
2009
2011
2013, 2014 both positive
NA
Data not clear if was on steroid in first or last relapse, but was on immunosuppressant when tested positive for MOG-IgG
2
2004
2011
2015
2014
2014
2014
2015, 2016, 2017 all positive
300
Patient was not on steroid in first or last relapses, but was on immunosuppressant when tested positive for MOG-IgG after diagnosis and remained positive
3
Jan 99
Apr 03
May 03
Unknown
2003
Apr 14
Jul 14 positive
NA
Data not clear if was on steroid in first or last relapse, but was on immunosuppressant when tested positive for MOG-IgG subsequently
4
Sep 14
Nov 14
May 17
Nov 14
Dec 14
2014
2015 positive
300
Patient was not on steroid in first relapse, but was on steroid and immunosuppressant in last relapse and when MOG-IgG tested and remained positive
2016 positive
400
5
Sep 10
Oct 10
Jul 13
At onset
2011
2012
2014, 2015, 2016 all positive
NA
Patient was on reducing dose of steroid in first relapse, and on immunosuppressant and steroid in last relapse and when MOG-IgG was tested and remained positive
6
Aug 13
Sep 14
Sep 14
Sep 14
May 15
Sep 14
2016, 2017 both positive
NA
Patient was not on steroid in first relapse, was on steroid when tested for MOG-IgG initially and in 2016 but off steroid in 2017 and remained positive
7
2001
2004
2010
At onset
2010
2013
2014, 2016 both positive
NA
Patient was not on steroid in first or last relapse, she was on immunosuppressant when tested for MOG-IgG subsequently.
8
Jul 08
Nov 08
Nov 08
At onset
Nov 08
Apr 11
May 11 positive
NA
Data unavailable if patient was on steroid in first relapse, she was on immunosuppressant when tested positive for MOG-IgG
9
Apr 12
Jul 12
Aug 15
At onset
2012
2012
2015, 2016 positive
NA
Patient was on steroid in first relapse and when tested positive for MOG-IgG. She was also positive when was on steroid and immunosuppressant in subsequent relapses.
10
Mar 07
Jul 13
Dec 15
At onset
Jul-14
Apr 14
2016 positive
NA
Patient was not on steroid in first relapse, or first MOG-IgG test. He was on immunosuppressant in last relapse and when remained positive in subsequent testing
11
1984
2001
Mar 13
At onset
2013
2015
No further tests
NA
No available data whether patient was on steroid in first or last relapse, but he was on immunosuppressant when tested positive for MOG-IgG.
12
May 12
Aug 14
Aug 14
At onset
May 15
May 15
2016 positive
NA
Patient was not on steroid in first relapse, but was on steroid when tested positive for MOG-IgG and was on immunosuppressant on subsequent positive test
13
Oct 12
Jan 13
Jan 13
At onset
Aug 13
Jul 13
2014 negative
2015 positive
NA
Patient was on steroid in first relapse, however, immunosuppressant was initiated after MOG-IgG returned positive in 2013, later test one year apart was negative in 2014, and subsequent test in 2015 was positive while still on immunosuppressant
14
Mar 14
At onset
Apr 14
Apr 14
2015, 2016, 2017 all positive
NA
Only one event but patient chose to go on treatment
15
Jun 12
At onset
Not on immunosuppressant
Jun 12
2015 positive
NA
Not on immunosuppression
Discussion
In a cohort of well-characterised NMOSD patients (n = 132), 73% were AQP4-IgG and 11% were MOG-IgG seropositive and 16% remained seronegative. MOG-IgG disease accounts for 42% of the AQP4 IgG-negative seronegative cohort. MOG-IgG was present in 38% of patients with long myelitis and optic neuritis who do not have AQP4 IgG.
86% (13/15) of our patients who satisfy criteria for NMOSD who are MOG-IgG-positive patients have relapsing disease, similar to a recent study [7] who reported that 80% of their MOG-IgG-positive cohort (n = 50) followed a relapsing course. However, a relapsing course was the reason for referral to the clinic in the first place (n = 13/13) making this a biased sample. Long-term follow-ups of a cohort of MOG-IgG-positive patients after the very first event is required to obtain the true risk of relapse.
Importantly, 20% of patients with non-MS/atypical demyelination who do not satisfy criteria for NMOSD tested positive for MOG-IgG (Fig. 1). Double positive cases (both AQP4-IgG and MOG-IgG) are rare [8‐10] with none of the tested patients were definite positives. Since we have tested only 52% (68/132) of the total NMOSD cohort for MOG-IgG, this requires further clarification in future studies.
In conclusion, our study provides the best possible answers at the current time on several questions on the frequency of MOG-IgG patients: NMOSD who are AQP4-IgG negative and MOG-IgG positive (42%), NMO (as per Wingerchuk 2006) with optic neuritis and long myelitis who are AQP4-IgG negative but MOG-IgG (13%). We also found that MOG-IgG is found in 20% of non-NMOSD/non-MS demyelination. It is also estimated that at least 11% of all NMOSD (as per 2015 criteria) is MOG-IgG positive.
Our study has important practical implications. First, the definite diagnosis of MOG-IgG-associated disease offers patients and physicians a better diagnostic label than seronegative NMOSD. Second, as nearly one in every two of seronegative NMOSD, and 1/5 of atypical non-MS demyelination is MOG-Ig positive, testing for these cohorts will be of high yield and worthwhile, compared to testing every demyelination (which in most Caucasian predominant populations is likely to be MS) with attendant costs and risk of false-positive results. Third, it is likely that the long-term disease course and therefore treatment strategies of AQP4-IgG and MOG-IgG is different. If this is the case, MOG-IgG status, should be part of inclusion/exclusion criteria or a variable for stratification in clinical trials. The latter issue may have importance for currently recruiting trials that include seronegative NMOSD.
Compliance with ethical standards
Funding
The study is not industry sponsored.
Conflicts of interest
All authors declare no conflict of interest.
Anzeige
Ethical standards
This study meets UK ethical standards.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.
Mit e.Med Neurologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes, den Premium-Inhalten der neurologischen Fachzeitschriften, inklusive einer gedruckten Neurologie-Zeitschrift Ihrer Wahl.
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.
Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.
Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.
Update Neurologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
